Robert Leitz of iolite Capital presents BFF Bank (Milan: BFF), an Italian specialty factoring bank that buys receivables owed by state-owned hospitals and other public administrations to their suppliers, chiefly in healthcare. The investment case rests on a simple observation: the Italian state always pays, just late—typically three to five years—with a historical recovery rate near 99.99%. Because EU law entitles holders to statutory late-payment interest of roughly 8% over the ECB reference rate, BFF effectively monetizes a regulated rent stream rather than negotiating it. The bank operates across nine countries and is a market leader in Poland and Spain, and its banking licence gives it access to cheap ECB funding. The unit economics are compelling: receivables are bought at a small discount, accrue interest over several years against a blended funding cost of about 2.55%, and deliver a net spread around 6.8%. A less visible asset is roughly €6.6bn in near-zero-cost overnight deposits sourced from BFF’s payment services (serving 130-plus mid-tier institutions) and securities services (300-plus regulated funds), essentially free funding that can be deployed into sovereign debt—Leitz estimates that putting an additional €1bn into government bonds could add close to €100m in profit.
Against that earnings power, BFF trades at roughly €500m in market capitalization, about 3.8x normalized net earnings and around 60% of book value, a dislocation Leitz attributes to a regulatory dispute rather than any credit deterioration. In May 2024 a Bank of Italy inspection forced a reclassification of BFF’s public-sector loans, sending the stock down about 30% and prompting the dividend to be cancelled; in early 2026 Milan prosecutors opened a false-accounting probe, CEO Massimiliano “Max” Belingheri stepped down while remaining on the board, and two extraordinary commissioners were appointed alongside management, with adjusted net income guidance cut twice from €240m toward a €115–140m range. At the core is a classification anomaly: EU rules treat a receivable more than 90 days past due as “in default,” so exposures to a payer that reliably settles late are labelled defaulted, inflating capital requirements despite negligible actual losses. The subtext is political—Italy would prefer to keep its healthcare debt off the sovereign balance sheet, while EU regulation pulls the other way—leaving BFF a proxy for that debate and, in Leitz’s framing, a case where the problem is the labelling of valuable collateral, not its value.
Presentation summary generated by AI